Education Day of the Society for Neuro-Oncology
November 16, 2023


       

This activity is provided by the Society for Neuro-Oncology.

This activity is supported by educational grants from SpringWorks.

Target Audience
Neuro-oncologists (both neurology and medical oncology-trained), Medical Oncologists, Neurosurgeons, Neuro-radiologists, Neuropathologists, Neuropsychologists, Radiation Oncologists, Basic and Translational Scientists, Basic and Clinical Science Trainees, Allied Health Professionals, Palliative Care Professionals, Industry Professionals, Regulatory and Government Officials, Patient Advocates, and Nursing Professionals.

Statement of Need/Program Overview
As an adjunct to the 2023 SNO Annual Meeting, the Education Day on November 16 will feature specialized content focusing on Nervous System Tumor Susceptibility Syndromes: Neurofibromatosis, Tuberous Sclerosis, von Hippel Lindau and related syndromes. There will be two distinct tracks on this theme, one addressing basic science and the other addressing the applied and practical aspects of managing the care of patients with these challenging syndromes.

Educational Objectives

• Describe the mechanism of disease and the biology of the tumor microenvironment of the tuberous sclerosis complex.
• Identify clinical diagnostic techniques and therapies used in the treatment of patients with tuberous sclerosis.
• Describe the mechanism of disease and the biology of the tumor microenvironment of neurofibromatosis type 1 and neurofibromatosis type 2 related schwannnomatosis.
• Compare and contrast diagnostic criteria and treatment modalities used in managing the care of patients with neurofibromatosis type 1 and neurofibromatosis type 2 related schwannomatosis.
• Describe the mechanism of disease and the biology of the tumor microenvironment of von Hippel-Lindau disease.
• Identify genetic variations, screening approaches and therapeutic management of patients with von Hippel-Lindau disease.
• Summarize genetic testing requirements, genetic counseling needs and the clinical implications of genetic testing and counseling associated with the care of patients with tuberous sclerosis, neurofibromatosis and von Hippel-Lindau disease.

Program Agenda
Please click here. 

Physician Accreditation Statement
The Society for Neuro-Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation
The Society for Neuro-Oncology designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

SNO Contact Information
For more information about the accreditation of this program, please contact the Society for Neuro-Oncology CME Program Manager, MeLesa Ritterhouse, RN at melesa@soc-neuro-onc.org.

Instructions to Receive Credit
In order to receive credit for this activity, the participant must have attended the sessions in-person (you cannot claim CME for on-demand sessions), complete the education day evaluation and session evaluations by logging in to this website or the conference mobile app by using the users registration login. 

Click here for step-by-step instructions.

Deadline to claim CE Credit is Monday, February 12, 2024.

Refund/Cancellation Policy
The deadline for cancellations with refund is Thursday, November 2, 2023. Cancellations must be received in writing and a $50 cancellation fee will be assessed. Cancellations received after the deadline date cannot be refunded, but the meeting registration can be transferred to another person with written authorization..

Please note that your SNO membership must be current if you have chosen to register as a SNO member. SNO reserves the right to confirm that you have registered in the correct category.
 
Payment must be received in full before access to the meeting can be granted.

Email all cancellation and transfer requests to Program Registrar Caroline Noor, caroline@soc-neuro-onc.org.
  
Disclosure of Relevant Financial Relationships
The Society for Neuro-Oncology (SNO) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited Continuing Education, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME), stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of accredited continuing education program are required to disclose all financial relationships with any ineligible company within the past 24 months . All financial relationships reported are identified as relevant and mitigated by Society for Neuro-Oncology in accordance with the Standards for Integrity and Independence in Accredited Continuing Education in advance of delivery of the activity to learners. The content of this activity has been vetted to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by SNO. 

Please find the list of disclosures here. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Society for Neuro-Oncology does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.